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Abstract
Background: Acrolein is an air toxic and highly potent respiratory irritant. There is little epidemiology available, but US EPA
estimates that outdoor acrolein is responsible for about 75 percent of non-cancer respiratory health effects attributable to
air toxics in the United States, based on the Agency’s 2005 NATA (National-Scale Air Toxics Assessment) and acrolein’s
comparatively potent inhalation reference concentration of 0.02 mg/m3.
Objectives: Assess the association between estimated outdoor acrolein exposure and asthma attack reported by a
representative cross-sectional sample of the adult United States population.
Methods: NATA 2005 chronic outdoor acrolein exposure estimates at the census tract were linked with residences oif adults
($18 years old) in the NHIS (National Health Interview Survey) 2000 – 2009 (n = 271,348 subjects). A sample-weighted
logistic regression model characterized the association between the prevalence of reporting at least one asthma attack in
the 12 months prior to survey interview and quintiles of exposure to outdoor acrolein, controlling for potential confounders.
Results: In the highest quintile of outdoor acrolein exposure (0.05 – 0.46 mg/m3), there was a marginally significant increase
in the asthma attack pOR (prevalence-odds ratio [95% CI] = 1.08 [0.98:1.19]) relative to the lowest quintile. The highest
quintile was also associated with a marginally significant increase in prevalence-odds (1.13 [0.98:1.29]) in a model limited to
never smokers (n = 153,820).
Conclusions: Chronic exposure to outdoor acrolein of 0.05 – 0.46 mg/m3 appears to increase the prevalence-odds of having
at least one asthma attack in the previous year by 8 percent in a representative cross-sectional sample of the adult United
States population.
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Introduction
Acrolein is among the 189 pollutants designated under the 1990
Clean Air Act [1] to be a hazardous air pollutant (or air toxic)
known to or suspected of causing cancer or other serious health
problems. A simple aldehyde, acrolein (CAS 107-0-28; IUPAC
prop-2-enal) is a potent irritant of the respiratory tract, including
the nose and throat [2–5]. Acrolein can also irritate the eyes and
skin [6,7]. Acrolein was deployed as a chemical warfare agent (tear
gas) at least once during World War I [8–11].
Acrolein is used mainly as a precursor in the manufacture of
acrylic acid and as a biocide. Acrolein is ubiquitous in the
environment, and since it is formed through the combustion of
petroleum (especially diesel fuel), acrolein is a concern for mobile
sources, aircraft, and industrial boilers [12]. Another major
component of mobile emissions — 1,3-butadiene — oxidizes in
the atmosphere to acrolein, further augmenting acrolein’s
presence in the environment. US EPA (United States Environ-
mental Protection Agency) estimates that approximately three-
quarters of ambient acrolein exposure originates from mobile
sources [13]. Acrolein exists in the atmosphere in the vapor phase,
and is subject to photochemical degradation by hydroxyl radicals,
ozone, and nitrate radicals. Acrolein’s half-life in the atmosphere
based on observed gas-phase photolysis indicates a half-life of 10.9
days [14], but calculated half-life estimates range from 3.4 hours to
28 days depending on the type of photolytic reaction [15–20].
Acrolein is also a major component of the vapor phase of
tobacco smoke, as well as smoke from cooking, forest fires, and
biomass combustion. Small amounts of acrolein have also been
detected in some foods, such as fried foods, cooking oils, and
roasted coffee [6,20–22]. Acrolein is also formed endogenously as
part of physiological oxidative stress response and polyamine
metabolism [23].
Although direct evidence of acrolein’s carcinogenicity in
humans or experimental animals is considered inadequate [24],
acrolein is known to induce DNA damage [25] and to form DNA
adducts relevant to lung cancer and inhibition of tumor
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suppression [26,27]. Acrolein has also been shown to interact with
a prominent carcinogenic constituent of tobacco smoke —
benzo[a]pyrene — to inhibit p53 tumor suppressor activity, which
suggests a role for acrolein in lung cancer initiation [28].
Attention has focused recently on the potential role of
endogenous acrolein — produced as part of oxidative stress
response — in a variety of neurologic disorders, such as
Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral
sclerosis [29–32]. Endogenous acrolein has also been observed in
connection to spinal cord injury [33], as well as myelin damage
[34]. The possibly adverse neurological effects of endogenous
acrolein have prompted concern about environmental exposure to
acrolein, particularly through air pollutant emissions and tobacco
smoke.
Acrolein’s role as a respiratory toxicant is well established [6,7].
Because of its high reactivity with human tissue, inhalation of
acrolein has been hypothesized to induce or exacerbate acute lung
injury and chronic obstructive pulmonary disease [21]. A risk
assessment for human lung function extrapolated from rat data
suggested that ambient concentrations of acrolein in the United
States may be associated with reduced respiratory function [35]. In
a comprehensive review considering the exposure prevalence and
toxic potency of hazardous air pollutants, acrolein was recom-
mended for further research into its role in the initiation and
exacerbation of asthma [36]. Other risk assessments of air toxics
have singled out acrolein as a prominent noncancer respiratory
health risk in the United States [37,38] and in Pittsburgh, PA [39].
Asthma is a chronic inflammatory disorder of the small
respiratory airways. Acute episodes, or asthma attacks, in
susceptible individuals are associated with airflow obstruction
characterized by wheezing, breathlessness, chest tightness, and
coughing. These episodes result from a combination of airway
inflammation and elevated bronchial hyperresponsiveness to a
variety of triggers. Important environmental triggers include ETS
(environmental tobacco smoke), dust mites, cockroach allergen,
outdoor air pollution, wood smoke, pets, and mold [40,41]. As a
potent respiratory irritant, acrolein may have a prominent role as
an environmental trigger of asthma attacks. Asthma attacks are
usually reversible, either spontaneously or with medication, and
while there is no cure for asthma, symptoms can be managed
through medication and the avoidance of environmental triggers
[42–44].
There are standard US EPA methods for measuring ambient
acrolein (Method TO-11a, based on a canister sampler, and TO-
15, a cartridge method), with temporal resolution of hours to days
[45,46]. Negative bias has been reported with Method TO-11a
[47]. A real-time quantum cascade laser infrared absorption
device is also commercially available [48]. Because acrolein is
highly reactive, ambient measurement remains notoriously diffi-
cult, which increases uncertainty about the consistency and
reliability of acrolein monitoring data [49,50]. Improving mea-
surement of ambient acrolein is the subject of ongoing research
[51,52].
With the difficulties in measuring ambient acrolein, it is not
surprising that there is scant epidemiologic research into the health
effects of acrolein in general populations. In striking contrast to
this lack of information, US EPA estimates that acrolein is
responsible for about 75 percent of non-cancer respiratory health
effects attributable to air toxics in the United States, based on the
Agency’s NATA (National-Scale Air Toxics Assessment) for 2005
[13]. Acrolein’s environmental ubiquity notwithstanding, its
prominence in risk assessments like NATA and others [35–39] is
driven primarily by its distinctively high potency for respiratory
health effects compared to other air toxics, with a chronic
inhalation RfC (reference concentration) of 0.02 mg/m3 [53].
The aim of this study was to provide empirical evidence of the
association between acrolein exposure and respiratory irritation, as
denoted by the prevalence of self-reported asthma attacks among
adults in the general population. This was achieved by geograph-
ically linking NATA 2005 acrolein exposure concentration
estimates at the census tract level with residences of participants
in NHIS (National Health Interview Survey) 2000 – 2009 [54].
NHIS data have been geographically linked to US EPA ambient
air monitoring data to examine the associated prevalence of
childhood asthma [55] and respiratory allergies [56,57], but this is
the first time that NHIS data have been linked to NATA exposure
estimates. Geographically linked NATA data has also been used to
study air toxics exposure and asthma in a children’s birth cohort
[58], cancer [59], and autism spectrum disorder [60,61].
Materials and Methods
National-Scale Air Toxics Assessment 2005
NATA 2005 estimates chronic inhalation exposure risks for 179
air toxics, and is a tool for prioritizing geographic areas, pollutants,
and emission sources for further evaluation of public health impact
[13]. US EPA developed NATA to augment data from the
Agency’s nationwide air toxics monitoring network by taking a
model-based approach to quantifying the potential health risks
from air toxics. NATA provides risk estimates for each of the
approximately 66,000 census tracts comprising the United States.
Census tracts are delineated by the US Census Bureau, and each
typically contains about 4,000 residents and ranges from 1,500 to
8,000 residents. Tracts also vary in geographic size, with urban
tracts usually smaller than two square miles and rural tracts being
much larger [62].
NATA encompasses outdoor emissions of air toxics from
stationary point sources, non-point sources, and mobile sources
(on-road and off-road), as well as estimates of background
concentration and secondary formation of acrolein from the
decay of 1,3-butadiene. In 2011, US EPA released NATA 2005
[13] based on 2005 National Emissions Inventory data [63], which
were the most complete and up-to-date inventory data at the time
of the analysis. NATA 2005 combines data from the National
Emissions Inventory and US EPA’s air monitoring system as
inputs to air dispersion and photochemical models (American
Meteorological Society/EPA Regulatory Model [AERMOD],
Assessment System for Population Exposure Nationwide Model
[ASPEN], and Community Multiscale Air Quality Model
[CMAQ]) to estimate outdoor air toxics concentrations. The air
dispersion models account for the physical topography and
population density in each census tract. The outdoor concentra-
tion estimates are then used as the basis for estimating chronic air
toxics exposure concentrations from a screening-level inhalation
exposure model (Hazardous Air Pollutant Exposure Model,
Version 5: HAPEM5). These exposure concentrations account
for differences in exposure resulting from demographics, human
activities, commuting patterns, climate data, and indoor-to-
outdoor variability. The NATA process concludes with estimation
of cancer and non-cancer public health risks [64], but for the
analyses reported here only the acrolein inhalation exposure
concentrations estimated at the census tract level were used. And,
unlike NATA health risk estimates, NATA exposure concentration
estimates do not utilize unit health risk factors like the RfC.
Acrolein and Asthma Attack in US Adults
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National Health Interview Survey 2000 – 2009
NHIS is conducted by NCHS (National Center for Health
Statistics) of the CDC (Centers for Disease Control and
Prevention) and is a principal source of information on the health
conditions, behaviors, and access to health services of the civilian,
non-institutionalized population of the United States. Information
is collected through a comprehensive interview of a nationally
representative cross-section of households [65]. NHIS is designed
to produce national estimates of disease prevalence, and provides
reliable data for estimating asthma prevalence across the United
States, over time, and across subgroups [66]. Sampling is
conducted annually following a multistage area probability design
that permits the representative sampling of households and
noninstitutional group quarters (e.g., college dormitories). This
study evaluated the cross-sectional prevalence of having at least
one self-reported asthma attack in the 12 months prior to each
subject’s interview, which represented affirmative answers to both
NHIS questions ‘‘Have you ever been told by a doctor or other
health professional that you had asthma?’’ and ‘‘During the past
12 months, have you had an episode of asthma or an asthma
attack?’’ This definition identifies subjects with symptomatic
asthma and is the standard CDC definition for evaluating asthma
attack prevalence [55].
Additional NHIS data on potential confounders were evaluated
in the logistic regression models: sex, age, race/ethnicity, poverty
status, education, health insurance coverage, access to health care,
whether the subject’s residence was located in an urban or rural
area, as well as NHIS interview year and calendar quarter.
Acrolein is a component of tobacco smoke, so smoking status
(never smoked, former smoker, and current smoker) was evaluated
as a potential confounder and separate models were fit for never
smokers and never & former smokers. Information for potential
confounders was reported by the participant or an adult in the
participant’s household, except for poverty and insurance status,
urban residence, survey year, and calendar quarter. Poverty status
of each subject’s family was determined according to a calculated
PIR (poverty income ratio): the ratio of family income to the US
Census poverty threshold adjusted for family size. Families with a
PIR ,1.00 were categorized as poor. The uninsured were subjects
who did not have health insurance at the time of the interview
under private health insurance, Medicare, Medicaid, State
Children’s Health Insurance Program, a state-sponsored health
plan, other government programs, or military health plan.
Insurance status for the subject may have been reported by an
adult in the subject’s family. This definition of uninsured matches
that used in Health United States [67]. Access to health care was
assessed through the NHIS question ‘‘Is there a place that you
usually go to when you are sick or need advice about your health?’’
Relevant places include hospital emergency rooms and outpatient
departments. Residence in an urban or rural area followed US
Census Bureau classification and is available from restricted-use
NHIS data files.
NATA-NHIS Linked Data and Statistical Models
One adult 18 years of age or older was randomly selected from
each participating NHIS family to provide detailed information
about their health, including symptomatic asthma and smoking
status. This study compiled ten years of data (2000 – 2009)
regarding these sample adults, numbering 287,530 subjects [54].
Of these, 9,524 subjects were missing census tract information,
and another 6,658 subjects were missing data on the outcome or
predictors. This left 271,348 subjects (94.4 percent) who were
included in the logistic regression models reported here. The
Census 2000 tract identifiers for NHIS subjects’s residences are
available from restricted-use NHIS data files, which enabled
assignment of subjects to their respective census tracts. Using
Census 2000 tract delineations, NATA acrolein exposure data at
the census tract were geographically linked with health outcome
data for individual NHIS subjects.
Since NHIS is a complex survey in which subjects are obtained
through a multistage sampling design involving stratification,
clustering, and oversampling of specific population subgroups, the
complex design must be accounted for in order to ensure properly
estimated variances of regression coefficients obtained from
statistical models of NHIS data [66,68]. Robust estimation of
these variances may be accomplished through a generalized
estimating equations approach incorporating Taylor series linear-
ization and applying sampling weights to each survey subject. This
approach was used as it was implemented by the CROSSTAB,
DESCRIPT, and RLOGIST subroutines of SUDAAN version
10.0.1 [69] called from the SAS version 9.3 statistical software
application [70]. To parameterize the variance estimation
procedure, variables indicating the NHIS sampling stratum and
primary sampling unit were used. Pursuant to NCHS guidance
[71,72], sampling strata were renumbered to distinguish strata
used in different NHIS sample design periods: 2000 – 2005 and
2006 – 2009. In addition, the final annual sample weights from the
NHIS 2000 – 2009 sample adult files (WTFA_SA) for subjects 18
years old and older were adjusted for incomplete data (see below).
To yield annualized totals, sample weights were divided by ten,
which accounts for combining data across ten NHIS sampling
years [71,72].
Sample-weighted logistic regression models were fit to the linked
NATA-NHIS data where the dichotomous outcome was whether
an NHIS subject answered affirmatively that they had both ever
been diagnosed with asthma and had at least one asthma attack in
the previous 12 months. The reference outcome group comprised
NHIS subjects who: a) answered affirmatively that they had ever
been diagnosed with asthma, but answered negatively that they
had had at least one asthma attack in the previous 12 months; and
b) answered negatively that they had ever been diagnosed with
asthma. The predictor of interest was the quintile of NATA 2005
chronic inhalation exposure concentration to acrolein for the
census tract where the NHIS subject resided. Additional predictors
representing potential confounders (described above) were evalu-
ated in the regression models.
Acrolein is a prominent component of tobacco smoke, so it is
important to assess acrolein’s influence on asthma attack
prevalence among subjects who do not smoke. This was evaluated
in two sample-weighted logistic regression models for NATA-
NHIS 2000 – 2009 subjects limited to those reporting: a) that they
never smoked (‘‘never smokers’’; n = 153,820); and b) that they
either never smoked or were former smokers (‘‘never & former
smokers’’; n = 212,537). No subjects in these strata were current
smokers, but the second, larger stratum enabled us to evaluate the
potential influence of discontinued smoking. The predictors in
both stratified models were identical to the unstratified, except that
the stratified models did not control for smoking status. Statistical
significance was set at a#0.05, and marginal significance was set
at 0.05,a#0.15.
Among all NHIS 2000 – 2009 sample adults, 24.0 percent were
missing information on PIR, which derives from the historic
difficulty of obtaining self-reported income data. To address this
problem, NCHS provides multiply imputed data on income and
PIR. Specifically, for each subject, NCHS provides public-use PIR
data that have been imputed five times [54], which were included
in the statistical analyses reported here. Statistical analysis of
multiply imputed data yields multiple results that can be combined
Acrolein and Asthma Attack in US Adults
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to obtain unified variance estimates that reflect the additional
variation due to the multiple imputation procedure [73]. Earlier
evaluation of the performance of multiply imputed NHIS income
data indicated that it corrects biases that would otherwise occur
without multiple imputation and that statistical efficiency is
improved [74]. Consistent with NCHS guidance [75], this
approach was adopted through the use of the MI_VAR option
in the CROSSTAB and RLOGIST subroutines of SAS-callable
SUDAAN version 10.0.1. All results reported here and the sample
size described above are based on multiply imputed PIR data.
Regression models require complete information on all depen-
dent and predictor data for each subject, which were available for
271,348 of 287,530 subjects (94.4 percent) in the NATA-NHIS
linked data. Since subjects with incomplete data were not part of
the statistical models reported here, model estimates would have
been biased to the degree there was non-randomness in the
pattern of missing data. To ameliorate this potential bias, the
original NHIS survey sample weights (WTFA_SA) were adjusted
prior to statistical analysis using the WTADJUST subroutine of
SAS-callable SUDAAN version 10.0.1, which treats those subjects
with complete information as a random subsample of all NHIS
subjects. In this approach, the probability of an NHIS subject
being selected into this subsample was assumed to be a logistic
function of covariates. The parameters of this logistic selection
model were estimated implicitly by WTADJUST in adjusting the
sample weights. This approach is pursuant to current NCHS
guidance [76], and because all models reported here used sample
weights adjusted in this manner, results may be considered
statistically representative of the United States civilian, noninsti-
tutionalized adults comprising the NHIS study population [77].
Ethics Statement
The NCHS Research ERB (Ethics Review Board) protected the
rights and welfare of participants in the NHIS. In accordance with
Federal regulations, the NCHS ERB reviewed and approved
NHIS protocols and any changes made to them. This process
ensured the ethical treatment of NHIS participants. Documented
signed informed consent was obtained from each participant.
Results
Figure 1 displays the NATA 2005 acrolein exposure concen-
tration quintile for each census tract in the contiguous United
States overlaid with locations of 102 facilities that reported to the
2010 Toxic Release Inventory [78] (accessed through TOXMAP
[79]) that they released acrolein to the air on-site categorized by
the quintile of the amount released. This map demonstrates how
acrolein exposure is more widespread than suggested by the
locations of emitting facilities, which is consistent with the
prominence of mobile sources for acrolein exposure.
Table 1 displays the sample-weighted proportion of subjects
across acrolein exposure quintiles and across demographic
characteristics among the 271,348 adult subjects comprising the
NATA-NHIS data used in the logistic regression models. The
national sample-weighted prevalence of 12-month asthma attacks
was 3.8 (standard error: 0.1) percent among adults during 2000 –
2009. Because assignment of subjects to acrolein exposure quintiles
did not account for sample weighting, the sample-weighted
distribution of subjects among acrolein quintiles reported in
Table 1 do not appear even. Table 2 summarizes the distribution
of outdoor acrolein exposure concentrations: the sample-weighted
median acrolein chronic inhalation exposure concentration was
2.5E-2 (IQR: 3.2E-2) mg/m3, with a range from 1.4E-4 to 4.6E-
1 mg/m3.
Based on the sample-weighted logistic regression model for
NATA-NHIS 2000 – 2009 subjects reported in Table 3 (com-
prising the same data described in Table 1), there was a marginally
significant (p-value = 0.10) increase in the 12-month asthma attack
pOR (prevalence-odds ratio) of 1.08 [95% CI (95 percent
confidence interval): 0.98:1.19] at the highest exposure quintile
(5.5E-2 to 4.6E-1 mg/m3) relative to the lowest quintile (1.4E-4 to
1.1E-2 mg/m3), controlling for sex, age, race/ethnicity, poverty
status, education, smoking status, access to health care, whether
the subject’s residence was located in an urban or rural area, and
NHIS interview year. The reference group for this model was 35 –
44 year old, non-Hispanic white, non-smoking males, with one or
more places to go for medical care or advice, and educational
attainment of a high school diploma or more, who were
interviewed in 2005, and were living in an urban household with
a poverty index $1.00. Health insurance coverage and NHIS
interview quarter were initially included in the model, but since
they were not statistically significant they were dropped. For the
second through fourth acrolein exposure quintiles (1.1E-2 to 5.5E-
2 mg/m3), pORs ranged from 1.01 to 1.02 and were statistically
indistinguishable from asthma attack prevalence in the lowest
quintile of acrolein exposure.
Among adult never smokers and never & former smokers
(Table 3), the prevalence-odds of having at least one asthma attack
in the previous 12 months was 13 percent [1.13, 95% CI:
0.98:1.29] and 9 percent [1.09, 95% CI: 0.98:1.22] higher at the
highest acrolein exposure quintile compared to the lowest quintile.
These elevated prevalence-odds, however, had marginally signif-
icant p-values of 0.08 and 0.13. Additionally, there was a
marginally significant 11 percent increase in asthma attack
prevalence-odds in the third acrolein exposure quintile compared
to the lowest (p-value = 0.11), but this pattern was confined to
never smokers.
Discussion
In a representative cross-sectional sample of the adult civilian,
non-institutionalized population of the United States for 2000 –
2009, chronic residential exposure to outdoor acrolein (estimated
for 2005) at the highest quintile of 0.05 – 0.46 mg/m3 was found to
increase the prevalence-odds of having at least one asthma attack
in the previous 12 months relative to the lowest quintile by about 8
percent at a marginally significant level, as estimated in a sample-
weighted logistic regression model and controlling for potential
confounders. Since the NHIS data were pooled over 2000 – 2009,
statistical estimates are interpretable as being averaged over the
time interval of the pooled data [71,72].
These marginally significant results among adults are worth
comparing to a recent study of a nationally representative cohort
of United States children followed since infancy (n = 6,950) [58].
Adopting a somewhat different approach to using the NATA
estimates, this study geographically linked by zip code air toxics
respiratory health risk estimates from NATA 2002 to cohort
subjects in order to evaluate associated changes in asthma
prevalence. This study found no evidence of significantly increased
prevalence of asthma associated with total air toxics respiratory
health risk. The important differences between the designs of
Stoner, Anderson and Buckley [58] and the present study
notwithstanding, it is notable that although both utilized long-
term averages derived from NATA, neither respiratory risk
exposure comprising all air toxics [58] nor ambient concentration
exposure for acrolein was strongly associated with increased
asthma prevalence. This may point to the larger difficulty of
associating short-term, acute health episodes with long-term
Acrolein and Asthma Attack in US Adults
PLOS ONE | www.plosone.org 4 May 2014 | Volume 9 | Issue 5 | e96926
average exposure rather than, say, coincident real-time exposure
measurements that captures highly resolved temporal spikes in
exposure more relevant to the health outcome.
The highest quintile of acrolein exposure concentration was
more than double the chronic inhalation RfC of 0.02 mg/m3 [53]
and encompassed California OEHHA’s (Office of Environmental
Health Hazard Assessment) chronic REL (reference exposure
level) of 0.35 mg/m3 [80]. The acrolein exposure concentration
quintile encompassing the RfC — the second quintile of 0.01 –
0.02 mg/m3 — was not associated with significantly increased
asthma attack prevalence-odds. The importance of these compar-
isons should be viewed in light of the uncertainty factor for
acrolein’s RfC, which is 1000 [53], and REL, which is 200 [80].
Elevated rates of adverse respiratory health effects, including
asthma, have been widely observed among residents, especially
children, living near heavily trafficked roadways [81–87]. Adverse
respiratory health effects have been also correlated with traffic-
related air pollutants like particulates, nitrogen dioxide, and sulfur
dioxide [88–91]. Acrolein is a constituent of the complex mixture
of traffic-related pollutants that are implicated in short-term,
respiratory (non-cancer) health effects like asthma attacks. Since
traffic density is correlated with urbanization, competing effects
from other traffic-related air pollutants were accounted for by
including urban residence as a model predictor, but this statistical
adjustment is likely incomplete. While acknowledging these
considerations, acrolein is distinguished among air toxics because
of its high potency for respiratory (non-cancer) health effects.
Among the 85 substances that have inhalation RfCs listed on US
EPA’s Integrated Risk Information System [53], only two have
more toxic RfCs: chromium (VI; aerosol) and 1,6-hexamethylene
diisocyanate. Twenty-seven substances have RfCs that are within
two orders of magnitude less toxic than acrolein’s, including 1,3-
butadiene, acrylonitrile, and chromium (VI; particulate), but these
three air toxics are of concern because of their cancer health risks
[37], contrasted with the non-cancer health risk posed by acrolein.
And while some studies have been put forward to support a
proposal to relax acrolein’s RfC from 0.02 to 0.62 mg/m3 (0.27
ppb) [92–94], acrolein would still be a major concern among air
toxics at this proposed level.
Acrolein is a component of tobacco smoke, but both stratified
non-smoker models suggest that outdoor acrolein’s adverse effect
on asthma attacks does not appear to be driven solely by acrolein
inhaled directly from smoking tobacco.
Figure 1. Map of the contiguous United States indicating the NATA 2005 acrolein exposure concentration quintile [mg/m3] for each
census tract (shaded areas) overlaid with locations of 102 facilities reporting on-site air releases of acrolein [lbs] to the 2010 Toxic
Release Inventory (bubble size corresponds to quintile of acrolein released).
doi:10.1371/journal.pone.0096926.g001
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Although it would have been desirable to also evaluate the
influence of ETS, during 2000 – 2009 NHIS only asked about
ETS in 2005. Restricting analysis to a single year of data would
have curtailed statistical power so severely as to hinder proper
evaluation of ETS as a potential predictor of asthma attack
prevalence.
Median outdoor 24-hour measurements of acrolein at down-
town urban sites (Pittsburgh, PA) ranged from 0.11 – 0.14 mg/m3
[39]. NATA focuses on outdoor sources of acrolein, and so ignores
influences of indoor origin, such as cooking and building materials.
Acrolein levels in indoor air, however, have been observed to be
higher than outdoors. In a comprehensive quantitative literature
review of indoor hazardous air pollutants in United States
residences [95], the median concentration for acrolein was
estimated to be 0.84 mg/m3, nearly double the maximum
estimated outdoor exposure concentration in NATA 2005. Logue,
McKone, Sherman and Singer [95] also concluded that acrolein
should be considered a priority chronic and acute hazard among
chemical air contaminants. Using a mist chamber technique,
indoor acrolein measured in nine California homes in the morning
averaged 4.0 (standard deviation: 2.2) mg/m3, while simultaneous
outdoor measurements averaged 0.58 (0.64) mg/m3 [96]. In the
same study, substantial diurnal fluctuation in indoor acrolein
ranging up to a factor of 2.5 was correlated with cooking and
ambient temperature. In a model-based exposure assessment of
the United States population, nonsmokers exposed to indoor ETS
by living with a smoker were estimated to be exposed to acrolein in
a range from 1.6 to 3.6 mg/m3 [97]. Evaluated with respect to the
marginally significant increase in asthma attack prevalence-odds
reported here in the acrolein range of 0.05 – 0.46 mg/m3, the
higher indoor acrolein levels described above suggest that indoor
exposure may further increase asthma attack prevalence in the
general population.
In order to link NATA acrolein exposure estimates with NHIS
asthma data, NHIS subjects living in the same census tract were
assigned the same NATA acrolein exposure concentration. This
approach, however, ignores: a) intra-tract exposure variation; b)
exposure subjects may have obtained in other Census tracts; c)
differences in time subjects resided in a census tract. In the
temporal domain, NHIS subjects were assigned the same 2005
acrolein exposure estimate across all NHIS surveys from 2000 to
2009, which ignores temporal variation in acrolein exposure.
Short-term, transient emissions profiles — such as startups,
shutdowns, malfunctions, and upsets — are not represented, so
NATA’s chronic exposure estimates for acrolein would tend to
underestimate total and acute exposure. In addition, estimates
from NATA 2005 do not reflect long-term trends in air toxics
exposure, as would be expected as air pollution regulations for
mobile and fixed sources are implemented and as older facilities
are retired.
Table 1. Characteristics of subjects comprising NATA-NHIS
2000 – 2009 data: 271,348 of 287,530 subjects (94.4 percent)
with 3.8 (0.1) percent (standard error) prevalence of at least





1st: 1.4E-4 –1.1E-2 mg/m3 21.7 (0.5)
2nd: 1.1E-2 – 2.1E-2 21.9 (0.5)
3rd: 2.1E-2 – 3.4E-2 20.7 (0.5)
4th: 3.4E-2 – 5.5E-2 18.8 (0.4)





18 – 24 years-old 13.0 (0.2)
25 – 34 18.0 (0.1)
35 – 44 20.0 (0.1)
45 – 54 19.2 (0.1)
55 – 64 13.6 (0.1)
65 – 74 8.7 (0.1)




Non-Hispanic Black/African American only 11.3 (0.2)
Non-Hispanic Other 5.5 (0.1)
Non-Hispanic White only 70.8 (0.3)
Smoking Status
Current Smoker 21.7 (0.1)
Former Smoker 21.9 (0.1)
Never Smoked 56.5 (0.2)
Education
High School Graduate or Higher 83.2 (0.2)
Less than High School Graduate 16.8 (0.2)
Poverty Income Ratio (Imputed)
1.00 or Higher 89.2 (0.1)
,1.00 (Poor) 10.8 (0.1)
Place to Go When Sick
No place 14.7 (0.1)
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NATA comprises a rigorous and complex process in environ-
mental health risk assessment encompassing the entire United
States. US EPA has emphasized, however, that NATA is a tool
primarily for prioritizing air toxics, emissions sources, and
geographic areas based on health risks [64]. This prioritizing
information, rather than being the final assessment of risk, instead
enables regulators to target resources for additional, more refined
studies. The NATA process itself is also continually refined, and
although NATA 2005 incorporated improvements in data and
modeling, US EPA has noted that further improvements are
possible in several areas to reduce uncertainty: emissions data
quality, monitoring data quality, representativeness of meteoro-
logic data, representativeness of background air toxics concentra-
tions, and atmospheric model formulation [64]. In addition, in a
quantitative comparison of model-based NATA 2005 estimates
with ambient monitoring data [49], NATA 2005 accurately
predicted ambient concentrations for several air toxics, but there
appears to be a tendency for NATA to underestimate concentra-
tions for others, which may be attributable to emissions sources
missing from the National Emissions Inventory, under-estimation
of emission rates, bias in monitoring techniques, and difficulties in
estimating background concentrations. Still, other studies indicate
that NATA estimates are reasonably reliable estimates of personal
exposure to ambient air toxics [98,99]. The limitations of NATA
estimates described above would contribute to exposure misclas-
sification, adding a degree of uncertainty to the significance of the
estimated association between outdoor acrolein exposure and
asthma attack prevalence.
A distinct feature of NHIS is that it is conducted as a serial
cross-sectional survey, hence a causative relationship between the
dependent variable and the predictors cannot be concluded based
on the models alone, but must be evaluated in context of
dispositive epidemiologic and toxicologic evidence [100]. A
particular strength of this study is the large sample size of the
NATA-NHIS data, as well as its national representativeness and
comprehensive detail on subject characteristics, which enabled
good control of potential confounders for asthma attack preva-
lence in the logistic models, while at the same time examining the
effect of acrolein exposure.
This is the first report suggesting an association between
outdoor acrolein exposure and adverse effects on health in a
general population. This was achieved through the availability of a
rigorous model-based and geographically linked estimate of
exposure that accounts for human activity and microenviron-
ments. These exposure estimates also have the advantage of being
at a high spatial resolution that account for variation resulting
from local population density and topography. Model-based
exposure estimates provide one avenue of exposure assessment,
and although this report demonstrates the feasibility of conducting
national epidemiologic analysis for air toxics with modeled
Table 2. Sample-weighted statistics of outdoor acrolein exposure concentrations for NATA-NHIS 2000 – 2009 data.
Statistic Quantity [mg/m3]
Mean (SE) 3.4E-2 (3.6E-4)
Geometric Mean (geometric standard error) 2.3E-2 (2.3E-4)







Representative of the United States civilian, noninstitutionalized adult (. = 18 years) population.
doi:10.1371/journal.pone.0096926.t002
Table 3. Adjusted prevalence-odds ratios for having at least one asthma attack in the previous 12 months among a representative
cross-sectional sample of adult ($18 years-old) United States population.
All Subjects Never Smokers
Never & Former
Smokers
n = 271,348 n = 153,820 n = 212,537
Acrolein Exposure Quintile [mg/m3] pOR (95% CI) p-Value pOR (95% CI) p-Value pOR (95% CI) p-Value
1st: 1.4E-4 – #1.1E-2 Reference Reference Reference
2nd: .1.1E-2 – #2.1E-2 1.02 (0.94, 1.12) 0.61 1.07 (0.93, 1.22) 0.35 1.03 (0.92, 1.15) 0.60
3rd: .2.1E-2 – #3.4E-2 1.02 (0.93, 1.12) 0.69 1.11 (0.97, 1.27) 0.11 1.04 (0.94, 1.16) 0.46
4th: .3.4E-2 – #5.5E-2 1.01 (0.92, 1.11) 0.83 0.98 (0.86, 1.12) 0.77 0.97 (0.87, 1.08) 0.60
5th: .5.5E-2 – #4.6E-1 1.08 (0.98, 1.19) 0.10 1.13 (0.98, 1.29) 0.08 1.09 (0.98, 1.22) 0.13
Adjusted for sex, age, race/ethnicity, poverty income ratio (imputed five times), education, access to health care, whether a subject’s residence was located in an urban
or rural area, and NHIS interview year. The unstratified model for all subjects also controlled for smoking status, while the stratified models for never smokers and never
& former smokers did not.
doi:10.1371/journal.pone.0096926.t003
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exposure estimates, there continues to be a need for epidemiologic
studies to further establish acrolein’s risks in the general
population. This need will be addressed as methods for measuring
acrolein in ambient air continue to progress [51,52], and as recent
advances in measuring acrolein metabolites in human samples
become broadly applied [101].
Conclusion
Environmental exposure to acrolein arising from outdoor
emissions in the range of 0.05 – 0.46 mg/m3 was associated with
a marginally significant 8 percent increase in the prevalence-odds
of having at least one asthma attack in the past 12 months among
a representative cross-sectional sample of the 2000 – 2009 United
States adult civilian, non-institutionalized population, as estimated
in a sample-weighted logistic regression model controlling for
potential confounders. Outdoor acrolein exposure in this range
was also associated with marginally significant increases in asthma
attack prevalence-odds among adults who do not directly smoke
tobacco, a major source of acrolein exposure.
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